$CRDL.TO

Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment

Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis

Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association

Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.

Cardiol Therapeutics (CRDL.TO), up 3.6% in U.S. pre-market trading, is expanding its Phase 3 Maveric trial in the U.S. with seven additional clinical centers, the company said on Tuesday. The total number of clinical centers is expected to be 25.Patient enrollment surpassed the 50% threshold in early January and has now reached 75%, a statement added. Target recruitment is expected by the end of the second quarter but may extend into the third quarter to accommodate patient enrollment from additional clinical sites.The Maveric trial evaluating the company's lead candidate CardiolRx to prevent disease recurrence in patients with pericarditis. Phase 3 builds on the Phase 2 Maveric study, which demonstrated that CardiolRx produced "rapid and sustained" reductions in pericarditis pain and inflammation, along with a marked decrease in recurrent episodes per year. Data from the phase 3 trial is expected to support a new drug application with the FDA.Cardiol Therapeutics shares were last seen up US$0.05, to US$1.45 in New York trading.